AstraZeneca’s PARP drug Lynparza easily outscores chemo in PhIII breast cancer study
AstraZeneca appears ready to start broadening the market for its PARP inhibitor Lynparza. ASCO organizers picked the pharma giant’s Phase III data for HER-2 negative metastatic breast cancer for the Sunday spotlight. And it’s not hard to see why.
The drug was linked with tumor shrinkage in 60% of the patients with germline BRCA1 or BRCA2 mutations taking the drug, compared to 29% in the chemo group.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.